CA2956123C - 6-alkynyl-pyridine derivatives as smac mimetics - Google Patents
6-alkynyl-pyridine derivatives as smac mimetics Download PDFInfo
- Publication number
- CA2956123C CA2956123C CA2956123A CA2956123A CA2956123C CA 2956123 C CA2956123 C CA 2956123C CA 2956123 A CA2956123 A CA 2956123A CA 2956123 A CA2956123 A CA 2956123A CA 2956123 C CA2956123 C CA 2956123C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salts
- date
- date received
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14180554.9 | 2014-08-11 | ||
| EP14180554 | 2014-08-11 | ||
| PCT/EP2015/068349 WO2016023858A1 (en) | 2014-08-11 | 2015-08-10 | 6-alkynyl-pyridine derivatives as smac mimetics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2956123A1 CA2956123A1 (en) | 2016-02-18 |
| CA2956123C true CA2956123C (en) | 2023-02-14 |
Family
ID=51300621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2956123A Active CA2956123C (en) | 2014-08-11 | 2015-08-10 | 6-alkynyl-pyridine derivatives as smac mimetics |
Country Status (34)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR101479A1 (es) * | 2014-08-11 | 2016-12-21 | Boehringer Ingelheim Int | Derivados de 6-alquinil-piridina |
| EA038950B1 (ru) | 2016-05-19 | 2021-11-12 | Бёрингер Ингельхайм Интернациональ Гмбх | Способ получения производных 6-алкинил-пиридина |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| CN110475567A (zh) * | 2017-03-31 | 2019-11-19 | 勃林格殷格翰国际有限公司 | 抗癌组合疗法 |
| JP2022511437A (ja) | 2018-11-26 | 2022-01-31 | デバイオファーム インターナショナル エス．エー． | Ｈｉｖ感染の組み合わせ治療 |
| TW202600150A (zh) | 2019-01-25 | 2026-01-01 | 德商百靈佳殷格翰國際股份有限公司 | 編碼ccl21之重組棒狀病毒 |
| AU2020356356A1 (en) | 2019-09-25 | 2022-05-12 | Debiopharm International S.A. | Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma |
| BR112022023753A2 (pt) | 2020-06-03 | 2022-12-20 | Boehringer Ingelheim Int | Rhabdovírus recombinante que codifica para uma proteína de fusão fc de domínio extracelular cd80 |
| WO2024175554A1 (en) | 2023-02-21 | 2024-08-29 | Institut Curie | Trail agonists for use in the treatment of cancer in patients having an activating alteration of fgfr3 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060234360A1 (en) * | 2005-04-13 | 2006-10-19 | Paola Branduardi | Ascorbic acid production from D-glucose in yeast |
| AU2006255084A1 (en) | 2005-06-08 | 2006-12-14 | Novartis Ag | Organic compounds |
| WO2007101347A1 (en) | 2006-03-07 | 2007-09-13 | Aegera Therapeutics Inc. | Bir domain binding compounds |
| BRPI0720049A2 (pt) | 2006-12-07 | 2014-01-07 | Novartis Ag | Derivados de piridina utilizados como inibidores de xiap |
| US8859541B2 (en) * | 2012-02-27 | 2014-10-14 | Boehringer Ingelheim International Gmbh | 6-alkynylpyridines |
| US9249151B2 (en) | 2013-08-23 | 2016-02-02 | Boehringer Ingelheim International Gmbh | Bis-amido pyridines |
| US9278978B2 (en) | 2013-08-23 | 2016-03-08 | Boehringer Ingelheim International Gmbh | 6-Alkynyl Pyridine |
| AR101479A1 (es) * | 2014-08-11 | 2016-12-21 | Boehringer Ingelheim Int | Derivados de 6-alquinil-piridina |
-
2015
- 2015-08-07 AR ARP150102551A patent/AR101479A1/es active IP Right Grant
- 2015-08-10 PL PL15747820T patent/PL3180339T3/pl unknown
- 2015-08-10 TW TW104125989A patent/TWI723959B/zh active
- 2015-08-10 EA EA201790349A patent/EA031424B1/ru not_active IP Right Cessation
- 2015-08-10 DK DK15747820.7T patent/DK3180339T3/en active
- 2015-08-10 LT LTEP15747820.7T patent/LT3180339T/lt unknown
- 2015-08-10 CN CN201911357061.2A patent/CN111440164B/zh active Active
- 2015-08-10 MX MX2017001835A patent/MX2017001835A/es active IP Right Grant
- 2015-08-10 AU AU2015303308A patent/AU2015303308B2/en active Active
- 2015-08-10 JP JP2017507775A patent/JP6250226B2/ja active Active
- 2015-08-10 US US14/821,870 patent/US9481673B2/en active Active
- 2015-08-10 SG SG11201700999YA patent/SG11201700999YA/en unknown
- 2015-08-10 TR TR2019/02023T patent/TR201902023T4/tr unknown
- 2015-08-10 HR HRP20190336TT patent/HRP20190336T1/hr unknown
- 2015-08-10 WO PCT/EP2015/068349 patent/WO2016023858A1/en not_active Ceased
- 2015-08-10 RS RS20190219A patent/RS58355B1/sr unknown
- 2015-08-10 PT PT15747820T patent/PT3180339T/pt unknown
- 2015-08-10 ME MEP-2019-29A patent/ME03303B/me unknown
- 2015-08-10 HU HUE15747820A patent/HUE043915T2/hu unknown
- 2015-08-10 AP AP2017009718A patent/AP2017009718A0/en unknown
- 2015-08-10 KR KR1020177005822A patent/KR102445744B1/ko active Active
- 2015-08-10 ES ES15747820T patent/ES2711763T3/es active Active
- 2015-08-10 EP EP15747820.7A patent/EP3180339B1/en active Active
- 2015-08-10 SI SI201530611T patent/SI3180339T1/sl unknown
- 2015-08-10 PE PE2017000209A patent/PE20170193A1/es unknown
- 2015-08-10 BR BR112017002498-5A patent/BR112017002498B1/pt active IP Right Grant
- 2015-08-10 NZ NZ728073A patent/NZ728073A/en unknown
- 2015-08-10 CA CA2956123A patent/CA2956123C/en active Active
- 2015-08-10 CN CN201580039248.1A patent/CN106573930B/zh active Active
- 2015-10-08 UA UAA201702213A patent/UA118887C2/uk unknown
-
2016
- 2016-10-03 US US15/283,494 patent/US9801871B2/en active Active
- 2016-12-29 IL IL249844A patent/IL249844B/en active IP Right Grant
-
2017
- 2017-02-08 CO CONC2017/0001226A patent/CO2017001226A2/es unknown
- 2017-02-08 PH PH12017500231A patent/PH12017500231A1/en unknown
- 2017-02-08 CL CL2017000326A patent/CL2017000326A1/es unknown
- 2017-09-26 US US15/715,351 patent/US10413536B2/en active Active
-
2019
- 2019-02-19 CY CY20191100213T patent/CY1121273T1/el unknown
- 2019-08-02 US US16/530,084 patent/US20190358218A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2013346809B2 (en) | Triazolopyrazine | |
| CA2865467C (en) | 6-alkynyl pyridines as smac mimetics | |
| US9249151B2 (en) | Bis-amido pyridines | |
| US10413536B2 (en) | 6-alkyny-pyridine derivatives | |
| EP3036228B1 (en) | New 6-alkynyl pyridine compounds | |
| EP2978757A1 (en) | Indolinone analogues as brd4 inhibitors | |
| HK1232873A1 (en) | 6-alkynyl-pyridine derivatives as smac mimetics | |
| HK1232873B (en) | 6-alkynyl-pyridine derivatives as smac mimetics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200717 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD Year of fee payment: 10 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250728 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250728 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD Year of fee payment: 11 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260729 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260729 |